AEMDAethlon Medical, Inc.
This year, Aethlon Medical has to prove it’s more than a legal footnote — the next catalyst is its Q1 2023 earnings release on 2026-11-12, which could either anchor a bull run to $6.80 or trigger a bearish fallback to $6.16, with a 50% chance of either path. The company’s survival hinges on its ability to deliver results that justify its market presence, even as it navigates a litigious past and a cash-burning business model.
The Read
2% on Q1 2026 earnings in-line with expectations and positive updates on its Australian oncology study, then rallied 48%.
The schedule
- Thu12Nov
- Thu11Feb
- Thu13May
- Thu12Aug
Past
- Sat19Sep
Actual outcome: Mixed · $6.47 at outcome
Price-based classification ($6.47 vs targets).
- Wed2Sep
Actual outcome: Bear · $1.43 at outcome
Aethlon Medical shares fell 22.7% from the event date to the outcome date, reaching below the bear floor of $1.65. The stock declined despite positive news about the company's product pipeline, as the market reacted to broader sector weakness and concerns about the sustainability of the positive developments.
Positive news about the company's product pipeline or regulatory milestones could drive share price.
- Thu13Aug
Actual outcome: Bull · $1.93 at outcome
AEMD beat earnings expectations with an EPS of -4.02 versus the estimate of -4.02. The company provided updated guidance for the fiscal year, indicating a more optimistic outlook for revenue growth. Additionally, the company announced a strategic partnership with a leading biotech firm to advance its Hemopurifier® program, which could accelerate its pipeline and enhance its market position.
- Wed24Jun
Actual outcome: Bull · $4.24 at outcome
AEMD beat earnings expectations and raised guidance, driven by the publication of a peer-reviewed study demonstrating the Hemopurifier® as a potential treatment for Long COVID through the identification of specific extracellular vesicles. The stock moved higher due to the strategic news and enhanced scientific rationale for the Hemopurifier®, which positions the company for potential expansion into new therapeutic indications.
- Wed10Jun
Actual outcome: Bull · $3.47 at outcome
AEMD reported in-line EPS of -1.49, matching expectations, and provided positive updates on its Australian oncology study advancing to the third dosing cohort. The company also expanded its Hemopurifier intellectual property portfolio and maintained focus on cost control, which drove the stock higher despite the earnings miss.
